ADVFN - Advanced Financial Network.
HOME» NYSE » M » MRK Stock Price » MRK Stock News

Merck Share News

 Merck & Co., Stock Price
MRK Stock Price
 Merck & Co., Stock Chart
MRK Stock Chart
 Merck & Co., Stock News
MRK Stock News
 Merck & Co., Company Information
MRK Company Information
 Merck & Co., Stock Trades
MRK Stock Trades

J&J Provides Added Doxil Supply for Clinical Studies

By Peter Loftus Johnson & Johnson (JNJ) will provide additional supply of its cancer drug Doxil for use in clinical trials, including one testing whether the combination of an experimental Endocyte Inc. (ECYT) drug with Doxil improves treatment of ovarian cancer. Doxil has been in short supply since J&J's contract manufacturer experienced factory problems last year. Apart from affecting patients who were prescribed Doxil, the shortage also held up clinical trials of experimental drugs that were being tested with or against Doxil. J&J said Thursday it would provide supplies of Doxil to two clinical trials. One is a late-stage study testing whether Endocyte's EC145 and Doxil improves overall survival of women with ovarian cancer, versus Doxil alone. Endocyte said in a separate statement the additional Doxil would supplement an existing supply that was already in place to support the trial, and would allow the company to continue to enroll patients without interruption. Endocyte in April agreed to license EC145 to Merck & Co. (MRK), which gained global rights to develop and commercialize the drug in exchange for a $120 million up-front payment and up to $880 million in additional payments if certain milestones are met. Endocyte retains the right to co-promote the drug with Merck in the U.S. In addition, J&J will supply Doxil to be used in a clinical trial of VentiRx Pharmaceuticals' experimental cancer drug VTX-2337. J&J said its Doxil supplier, Boehringer Ingelheim's Ben Venue Laboratories unit, is making progress toward resuming production of Doxil near the end of this year. Ben Venue suspended production late last year as it tried to fix manufacturing problems identified by drug regulators. J&J has been allocating remaining supplies of Doxil through a rationing program. Earlier this year, the Food and Drug Administration approved the temporary importation of a replacement drug for Doxil, known as Lipodox. J&J said it will continue to pursue a shorter-term option to begin restoring Doxil supplies before the end of the year. Write to Peter Loftus at peter.loftus@dowjones.com Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stock News for Merck (MRK)
DateTimeHeadline
04/16/201508:03:02The Best Stock to Invest in Hep C
04/14/201513:30:00Phase III Trial of the Merck and NewLink Genetics Investigational...
04/14/201509:20:21Heat Biologics Is An Opportunity Among Soaring Immunotherapy...
04/14/201508:44:32The Growing Business Of Animal Healthcare
04/14/201507:00:00NewLink Genetics and Merck & Co Receives Vaccine Industry Excellence...
04/13/201521:12:18The New Dogs Of The Dow - Q1 2015
04/13/201518:02:26Merck CEO's 2014 Total Compensation Valued at $25 Million...
04/13/201517:26:06Statement of Changes in Beneficial Ownership (4)
04/13/201516:34:12Additional Proxy Soliciting Materials (definitive) (defa14a)
04/13/201516:33:18Proxy Statement (definitive) (def 14a)
04/13/201513:40:09Fitch Downgrades Merck
04/12/201515:56:23How the Hottest Biotech Sprouted in Iowa
04/12/201509:52:033 Best Dividend Stocks in Healthcare
04/11/201503:51:07Immunotherapy: Unleashing The Immune System To Decimate Cancer
04/09/201517:59:09Why Investors Shouldn't Worry About Explosive New Drug Pricing:...
04/09/201514:30:09Squabbles Over Testing Methods Hamper Search for Ebola Vaccine
04/09/201501:28:13Is Biogen A Buy? An Analysis Of Its Growth Drivers And Challenges
04/08/201516:50:52Why Advaxis Inc. Shares Soared Today
04/08/201512:38:48Merck's Buyback Report Card
04/08/201509:57:25Merck Gets Breakthrough Designation for Hepatitis C Drugs...

Merck and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad